AUS
NZ
UK
CA
USA
IND
Highlights:
hVIVO CEO, Yamin 'Mo' Khan, will present at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT.
The Jefferies Healthcare Conference is the largest of its kind in Europe, attracting over 650 healthcare companies and 3,000 attendees.
hVIVO, a leader in human challenge clinical trials, provides end-to-end services for testing infectious and respiratory disease products.
hVIVO plc (LSE:HVO), a leading contract research organisation (CRO) specializing in human challenge clinical trials, has announced that its CEO, Yamin ‘Mo’ Khan, will be presenting at the Jefferies Healthcare Conference in London on 19 November 2024. The presentation, scheduled for 12:00pm GMT, will be followed by one-on-one meetings with potential business partners and stakeholders.
The Jefferies Healthcare Conference is Europe's largest event dedicated to the healthcare sector, bringing together more than 650 healthcare companies, 3,000 attendees, and nearly 8,000 investor and business-to-business meetings. This prestigious event will feature a wide range of public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors across the Americas, Europe, the Middle East, Africa, Asia, and Australia.
hVIVO, a world leader in testing infectious and respiratory disease products, conducts human challenge clinical trials to evaluate vaccines and therapeutics. The company offers a comprehensive portfolio of services to its clients, which includes some of the largest global biopharma firms. hVIVO’s expertise spans across 11 human challenge models, with several new models in development. Additionally, the company provides specialist drug development consultancy services through its Venn Life Sciences brand and virology and immunology testing through its hLAB brand.
In 2024, hVIVO expanded its capabilities with the opening of new state-of-the-art facilities in Canary Wharf, London. This facility, the world’s largest commercial human challenge trial unit, includes on-site virology and immunology labs, outpatient units, and unique clinical trial recruitment capabilities through its FluCamp volunteer screening facilities in London and Manchester.
For further information, hVIVO’s CEO, Yamin ‘Mo’ Khan, and CFO, Stephen Pinkerton, are available for inquiries and will be meeting with conference participants throughout the event.
